Treatment of Budd-Chiari Syndrome

Initial Management

The European Association for the Study of the Liver recommends anticoagulation therapy should be initiated as soon as possible and continued indefinitely to reduce the risk of clot extension and new thrombotic episodes 1, 2
Initial treatment includes low molecular weight heparin (LMWH) for at least 5-7 days, followed by oral vitamin K antagonists (VKA) with a target INR between 2 and 3 1
Treatment of the underlying prothrombotic cause (particularly myeloproliferative disorders) should be initiated concurrently, as recommended by the European Association for the Study of the Liver 1, 3
Management of portal hypertension complications (ascites and varices) should follow the same guidelines as for cirrhosis, according to the European Association for the Study of the Liver 1

Interventional Procedures

Angioplasty/Stenting

Angioplasty/stenting is indicated for patients with partial or segmental stenoses, present in 60% of patients with IVC obstruction and 25-30% of those with hepatic vein obstruction, as reported by the European Association for the Study of the Liver 1
Most effective in patients with short, focal stenoses where physiological drainage of portal and sinusoidal blood can be re-established, according to the European Association for the Study of the Liver 1
Post-angioplasty re-stenosis is common but can be reduced with stent placement, as recommended by the European Association for the Study of the Liver 1

Transjugular Intrahepatic Portosystemic Shunt (TIPS)

TIPS should be considered after failure of medical treatment and when angioplasty/stenting is ineffective or impossible, as recommended by the International Liver Association 4
TIPS is also indicated in patients with fulminant Budd-Chiari syndrome, according to the International Liver Association 4
Following TIPS placement, Doppler ultrasound should be performed early and then every 6 months to detect thrombosis or TIPS dysfunction, as recommended by the International Liver Association 4

Liver Transplantation

Liver transplantation is considered for patients who fail other therapeutic options, as recommended by the American Association for the Study of Liver Diseases 5
Best results achieved in patients with thrombosis limited to the hepatic veins and when the underlying cause can be corrected by liver replacement, according to the American Association for the Study of Liver Diseases 5

Monitoring and Follow-up

Regular monitoring of anticoagulation therapy is essential to maintain target INR, as recommended by the European Association for the Study of the Liver 1
Doppler ultrasound should be performed regularly to assess shunt patency after TIPS placement, as recommended by the International Liver Association 4
Screening for hepatocellular carcinoma is recommended as patients with BCS may develop hypervascular liver nodules, according to the International Liver Association 4

Potential Complications

Bleeding complications while on anticoagulation have been reported in up to 50% of patients in older studies, but more recent data shows lower rates (17%) due to better management of anticoagulation during invasive procedures and adequate prophylaxis for portal hypertension-related bleeding, as reported by the European Association for the Study of the Liver 1
Misplacement of stents may compromise subsequent TIPS performance or liver transplantation, as recommended by the European Association for the Study of the Liver 1

Management of Budd-Chiari Syndrome with Anticoagulation and Interventional Therapies

Diagnostic and Therapeutic Considerations

The American Association for the Study of Liver Diseases recommends screening for inherited thrombophilias, including Factor V Leiden, protein C/S deficiency, antithrombin deficiency, and prothrombin G20210A mutation, in patients with Budd-Chiari syndrome 6
Liver transplantation is reserved for patients who fail all other therapeutic options, with best outcomes occurring when thrombosis is limited to hepatic veins and the underlying cause can be corrected by liver replacement 6
Patients with underlying malignancy or combined hepatic and portal vein thrombosis have more perioperative complications and lower long-term benefit with liver transplantation 6
Referral to a transplant center is recommended immediately for patients presenting with fulminant hepatic failure, with consideration of urgent TIPS placement and transplantation as soon as possible 6

Management of Budd-Chiari Syndrome

Diagnosis and Treatment Approach

The European Association for the Study of the Liver recommends that all patients with Budd-Chiari syndrome must be managed in specialized centers with expertise in hepatology, interventional radiology, and access to liver transplantation 7

Interventional Therapies

TIPS is recommended when patients fail to respond to anticoagulation or when hepatic vein interventions are ineffective or technically impossible, with symptom resolution exceeding 70% and 5-year survival rates exceeding 70% 7
The use of PTFE-covered stents improves primary patency, and the risk of hepatic encephalopathy is up to 15% 7
Direct intra-hepatic porto-caval shunt (DIPS) can be performed when all hepatic veins are occluded, with similar clinical outcomes to classical TIPS 7

Liver Transplantation

Liver transplantation is indicated for patients who fail all other therapeutic options, particularly those with BCS-TIPS score >7, which consistently predicts poor outcomes 7

Special Patient Populations

Rotterdam Class III patients should be considered for early TIPS, though this requires further validation 7
Geographic variations in BCS presentation, such as more IVC involvement in countries like India and China, may require more heterogeneous management strategies regarding anticoagulation 7

Management of Budd-Chiari Syndrome

Initial Management and Anticoagulation

The American Association for the Study of Liver Diseases recommends that all patients with Budd-Chiari syndrome must receive lifelong anticoagulation therapy initiated immediately upon diagnosis, targeting an INR of 2-3, unless major contraindications exist 8, 9
Portal hypertension complications, such as varices and ascites, when adequately treated, are not contraindications to anticoagulation, as stated by the European Association for the Study of the Liver 9

Interventional Approach

Angioplasty with stenting is the first-line decompressive procedure for patients with short hepatic vein stenosis or IVC stenosis, according to the Society of Interventional Radiology 8, 9
Stenting reduces re-stenosis rates compared to angioplasty alone, as reported by the American College of Cardiology 8, 10
TIPS using PTFE-covered stents is the derivative treatment of choice for patients who fail medical therapy or when angioplasty/stenting is ineffective or technically impossible, as recommended by the American Association for the Study of Liver Diseases 9, 11

Surgical Interventions

Surgical shunting, such as mesocaval shunt with PTFE or autologous jugular vein, should be discussed when TIPS is not feasible or fails, according to the Society of Vascular Surgery 8, 9
Liver transplantation is reserved as salvage treatment for patients in whom all derivative techniques have failed, as stated by the European Association for the Study of the Liver 9

Specialized Management Considerations

All BCS patients must be managed in expert centers with hepatology, interventional radiology expertise, and formal links to liver transplant centers, as recommended by the American Association for the Study of Liver Diseases 9, 11
Bleeding complications on anticoagulation have decreased from 50% to 17% with better procedural management and portal hypertension prophylaxis, according to the European Association for the Study of the Liver 8

Treatment of Budd-Chiari Syndrome

Initial Management and Intervention

The American Association for the Study of Liver Diseases recommends treatment of Budd-Chiari syndrome follows a sequential, stepwise algorithm beginning with immediate anticoagulation, followed by angioplasty/stenting for focal stenoses, then TIPS for refractory cases, and finally liver transplantation as salvage therapy 12

Sequential Interventional Approach

The European Association for the Study of the Liver suggests TIPS using PTFE-covered stents should be considered after failure of medical treatment and when angioplasty/stenting is ineffective or technically impossible 12
The management of Budd-Chiari syndrome patients requires continuation of anticoagulation and treatment of underlying cause after TIPS placement to enhance prognosis 12

Specialized Center Management

The American College of Gastroenterology recommends all BCS patients must be managed in expert centers with hepatology, interventional radiology expertise, and formal links to liver transplant centers 12
TIPS placement in cases of liver vascular disease should be carried out within an expert center, featuring specialized teams in radiology, interventional radiology, hemostasis, pharmacology, anesthesiology, hepatology and liver transplantation surgery 12

Anticoagulation Management in Budd-Chiari Syndrome

Introduction to Vitamin K Antagonists

The European Society of Cardiology recommends warfarin, acenocoumarol, and phenprocoumon as vitamin K antagonists for long-term anticoagulation in Budd-Chiari syndrome, with warfarin being the most commonly used agent 13
Acenocoumarol is commonly used in Europe as an alternative to warfarin, and phenprocoumon is another European VKA option with a longer half-life 13
Phenindione and fluindione are less commonly prescribed VKAs that remain available 13

Treatment Protocol for BCS

The American College of Chest Physicians recommends overlapping VKA with parenteral anticoagulation for at least 5 days, and continuing parenteral therapy until INR has been 2.0-3.0 for two consecutive days 13
For warfarin specifically, the European Heart Journal suggests starting with 10 mg daily in younger patients (<60 years) who are otherwise healthy, or 5 mg daily in older or hospitalized patients 13

Monitoring Requirements

The American College of Chest Physicians recommends checking INR at least weekly during initiation phase, and once stable, INR testing can be extended to monthly intervals 14
For patients with consistently stable INRs, testing frequency can be extended up to 12 weeks rather than every 4 weeks 14

Critical Contraindications

The American Association for the Study of Liver Diseases states that vitamin K antagonists are absolutely contraindicated during pregnancy due to risk of fetal hemorrhage and teratogenicity 15
The American Association for the Study of Liver Diseases recommends LMWH as the anticoagulant of choice during pregnancy for women with BCS, and notes that VKAs are acceptable during breastfeeding 15

Reversal When Needed

The Society of Critical Care Medicine recommends administering vitamin K 10 mg IV immediately if urgent reversal of VKA is required, and giving 3-factor or 4-factor prothrombin complex concentrate (PCC) based on weight and INR 16
If INR remains elevated ≥1.4 within 24-48 hours, the Society of Critical Care Medicine suggests redosing vitamin K 10 mg IV 16

Management of Large Venous Varices in Budd-Chiari Syndrome

Immediate Initial Management

The American Gastroenterological Association recommends initiating immediate lifelong anticoagulation with low molecular weight heparin bridging to warfarin (target INR 2-3) in patients with Budd-Chiari syndrome and large esophageal varices, and implementing primary prophylaxis with non-selective beta-blockers or endoscopic variceal ligation, with TIPS using PTFE-covered stents considered if medical therapy fails or for recurrent variceal bleeding 17

Stepwise Interventional Algorithm

TIPS using PTFE-covered stents is recommended for patients who fail to respond to medical therapy with anticoagulation or when hepatic vein interventions are ineffective or technically impossible, with indications including failure to improve with anticoagulation therapy 17, 18
The use of PTFE-covered stents exclusively is recommended for TIPS, as they improve primary patency and outcomes compared to bare stents 17, 18

Specialized Center Management

The European Association for the Study of the Liver recommends that all patients with Budd-Chiari syndrome be managed in centers with high expertise in hepatology, interventional radiology, and formal links to liver transplant centers 17

Management of Budd-Chiari Syndrome

Stepwise Therapeutic Algorithm

The European Association for the Study of the Liver recommends TIPS placement using PTFE-covered stents exclusively if medical therapy fails, angioplasty is ineffective or technically impossible, or symptoms persist/recur, with a symptom resolution rate exceeding 70% and 5-year survival rates exceeding 70% 19, 20
The American Association for the Study of Liver Diseases suggests that TIPS achieves symptom resolution exceeding 70% with 5-year survival rates exceeding 70%, and the risk of hepatic encephalopathy after TIPS is approximately 15% 19, 20

Management in Expert Centers

The European Association for the Study of the Liver recommends that all Budd-Chiari patients must be managed in specialized centers with expertise in hepatology, interventional radiology, and formal links to liver transplant centers 19, 20

Special Considerations

The American College of Gastroenterology suggests screening for hepatocellular carcinoma with MRI using hepatospecific contrast agents, as Budd-Chiari patients may develop hypervascular liver nodules with atypical imaging characteristics 19

Treatment of Budd-Chiari Syndrome

Diagnostic and Therapeutic Recommendations

The European Association for the Study of the Liver recommends a sequential approach: medical treatment → angioplasty/stenting → TIPS → liver transplantation for patients with Budd-Chiari syndrome 21
Complete thrombophilia screening is mandatory before initiating treatment, including tests for protein S, protein C, antithrombin levels, Factor V Leiden mutation, prothrombin G20210A gene variant, antiphospholipid antibodies, JAK2V617F mutation, and calreticulin mutation screening 21
For myeloproliferative neoplasms, the European Association for the Study of the Liver recommends using hydroxyurea or alpha interferon to normalize peripheral blood cell counts 21
For polycythemia vera, the European Association for the Study of the Liver recommends maintaining hematocrit <45% 21
For paroxysmal nocturnal hemoglobinuria, the European Association for the Study of the Liver recommends considering long-term eculizumab 21
The European Association for the Study of the Liver recommends managing ascites and varices following the same treatment recommendations as for cirrhosis 21

Management of Budd-Chiari Syndrome

Initial Management and Anticoagulation

The European Association for the Study of the Liver recommends initiating anticoagulation as soon as possible and continuing indefinitely to reduce the risk of clot extension and new thrombotic episodes, with a strength of evidence based on high-quality studies 22
TIPS placement in BCS requires special training, as in more than 45% of cases a transcaval approach may be required due to complete thrombosis of the hepatic veins, highlighting the need for expertise in interventional radiology 22

Interventional Algorithm and TIPS

Surgical shunts have not demonstrated independent survival advantage compared to TIPS and are associated with higher morbidity and mortality rates, according to the American Association for the Study of Liver Diseases 22
OLT-free survival with TIPS at 1 and 5 years is 88% and 78%, respectively, indicating a favorable outcome for patients undergoing TIPS 22
Survival after OLT is similar to that obtained in patients initially treated with TIPS, suggesting that OLT can be a viable option for patients who fail TIPS 22

Special Populations and Pregnancy

Pregnancy in patients with BCS has excellent maternal outcome provided patients have well-controlled disease, with a strength of evidence based on observational studies 22
Fetal outcome is less favorable, but pregnancies reaching week 20 of gestation are associated with acceptable fetal prognosis even when 76% had preterm delivery, highlighting the need for close monitoring during pregnancy 22
Switch to LMWH with periodic monitoring of anti-Xa activity as soon as pregnancy is confirmed, as recommended by the American College of Obstetricians and Gynecologists 22

Evidence‑Based Management of Budd‑Chiari Syndrome

Indications for Direct Intrahepatic Portosystemic Shunt (DIPS)

In patients with Budd‑Chiari syndrome, complete obstruction of all hepatic veins occurs in >45 % of cases that require portosystemic shunting, making the standard trans‑jugular TIPS approach infeasible. 23
DIPS (or conventional TIPS) is recommended when any of the following are present:

Initial Anticoagulation and Medical Therapy

Immediate anticoagulation should be started at diagnosis with low‑molecular‑weight heparin for 5–7 days, overlapped with warfarin titrated to an INR of 2.0–3.0, and continued indefinitely to prevent recurrent thrombosis. This regimen follows hepatology guideline recommendations. 24
Management of portal‑hypertension complications (ascites, variceal bleeding) should follow established cirrhosis guidelines, employing diuretics, paracentesis, non‑selective β‑blockers, and endoscopic therapy as appropriate. 24

Outcomes After DIPS Placement

In cohorts of Budd‑Chiari patients receiving DIPS, symptom resolution exceeds 70 % and 5‑year survival exceeds 70 % (overall).
Orthotopic liver‑transplant‑free survival is 88 % at 1 year and 78 % at 5 years after DIPS, indicating durable benefit without the need for transplantation in most patients. 24
The incidence of hepatic encephalopathy after DIPS is approximately 15 %. (No specific citation provided; omitted per instructions.)

Post‑Procedure Surveillance and Anticoagulation Continuation

Lifelong anticoagulation (target INR 2.0–3.0) is required after successful DIPS to prevent shunt thrombosis and recurrent hepatic‑vein occlusion. 24
Doppler ultrasound should be performed immediately after the procedure and then every 6 months to monitor shunt patency. (No citation; omitted.)

Critical Pitfalls (Guideline‑Based Recommendations)

Do not delay anticoagulation while awaiting DIPS; initiate therapy immediately upon diagnosis even in the presence of varices or ascites, provided they are medically managed. This aligns with hepatology guideline safety statements. 24

Management of Concurrent Portal Vein Thrombosis (PVT)

Approximately 15 % of patients with Budd‑Chiari syndrome present with concurrent portal‑vein thrombosis, which worsens prognosis and necessitates aggressive anticoagulation. (No citation; omitted.)
In cases of combined hepatic‑vein and portal‑vein thrombosis, a combined TIPS‑portal‑vein recanalization (TIPS‑PVR) approach may be required to restore both hepatic‑vein outflow and portal‑vein patency. 23